Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P51460
UPID:
INSL3_HUMAN
Alternative names:
Leydig insulin-like peptide; Relaxin-like factor
Alternative UPACC:
P51460; B4DZ72; G3XAG0; Q3KPI5; Q3KPI6; Q6YNB5; Q9UEA2; Q9UPH6
Background:
Insulin-like 3, also known as Leydig insulin-like peptide or Relaxin-like factor, encoded by the gene with accession number P51460, plays a pivotal role in testicular function. It is implicated as a trophic hormone essential for testicular descent during fetal development and acts as a ligand for the LGR8 receptor.
Therapeutic significance:
Given its crucial role in testicular development, Insulin-like 3 is linked to Cryptorchidism, a common congenital abnormality affecting 2-5% of male births, which can lead to infertility and testicular cancer. Understanding the role of Insulin-like 3 could open doors to potential therapeutic strategies for these conditions.